Luciano Severgnini
Overview
Explore the profile of Luciano Severgnini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reimann P, Petzer V, Mundlein A, Hartmann B, Severgnini L, Winkler A, et al.
Ann Hematol
. 2024 Mar;
103(6):2123-2131.
PMID: 38436671
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in...
2.
Muendlein A, Geiger K, Heinzle C, Gaenger S, Winder T, Severgnini L, et al.
J Cancer Res Clin Oncol
. 2023 Feb;
149(9):6435-6444.
PMID: 36763171
Purpose: RAS mutations are predictors of an adverse outcome in EGFR-targeted therapies and have been proposed as prognostic biomarkers of survival in metastatic colorectal cancer (mCRC). The analysis of circulating...
3.
Milbradt S, Eichhorn J, Fetzner U, Fietz R, Gross R, Jung K, et al.
Int J Cardiol
. 2022 Dec;
375:119-123.
PMID: 36535563
Background The reliability of the recommendations affecting the clinical decisions is being continuously weighed in everyday practice (Gershlick, 2018). The objective of our study was to assess the consistency of...
4.
Muendlein A, Severgnini L, Decker T, Heinzle C, Leiherer A, Geiger K, et al.
Front Oncol
. 2022 Nov;
12:1045995.
PMID: 36353562
Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have...
5.
Atzl M, Muendlein A, Winder T, Fraunberger P, Brandtner E, Geiger K, et al.
BMJ Open
. 2022 May;
12(5):e052130.
PMID: 35613821
Objectives: Austria, and particularly its westernmost federal state Vorarlberg, developed an extremely high incidence rate during the COVID-19 pandemic. Healthcare workers (HCWs) worldwide are known to have an increased risk...
6.
Berger J, Wohlfarth P, Konigsbrugge O, Knaus H, Porpaczy E, Kaufmann H, et al.
Wien Klin Wochenschr
. 2022 Feb;
134(9-10):371-376.
PMID: 35171337
Background: Cancer patients infected with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) have an increased risk of mortality. Here, we investigated predictive factors for coronavirus disease 2019 (COVID-19) associated...
7.
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, et al.
Br J Haematol
. 2021 Dec;
196(3):577-584.
PMID: 34872162
Patients with haemato-oncological malignancies are one of the high-risk groups for a severe course in case of COVID-19 infections. Furthermore, vaccination results in significantly lower response rates in haematological malignancies...
8.
Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, et al.
Br J Haematol
. 2021 Aug;
195(4):523-531.
PMID: 34346068
Haemato-oncological patients are at risk in case of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Currently, vaccination is the best-evaluated preventive strategy. In the present study, we aimed to assess...